PortfoliosLab logoPortfoliosLab logo
IMVT vs. AXSM
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

IMVT vs. AXSM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Immunovant, Inc. (IMVT) and Axsome Therapeutics, Inc. (AXSM). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, IMVT achieves a 49.88% return, which is significantly higher than AXSM's 35.70% return.


IMVT

1D
7.81%
1M
11.57%
YTD
49.88%
6M
38.34%
1Y
141.14%
3Y*
24.11%
5Y*
28.21%
10Y*

AXSM

1D
-1.06%
1M
5.03%
YTD
35.70%
6M
60.21%
1Y
146.15%
3Y*
41.16%
5Y*
28.89%
10Y*
42.66%
*Multi-year figures are annualized to reflect compound growth (CAGR)

IMVT vs. AXSM - Yearly Performance Comparison


2026 (YTD)2025202420232022202120202019
IMVT
Immunovant, Inc.
49.88%2.62%-41.21%137.35%108.33%-81.55%191.05%11.37%
AXSM
Axsome Therapeutics, Inc.
35.70%115.86%6.31%3.19%104.16%-53.63%-21.18%15.40%

Correlation

The correlation between IMVT and AXSM is 0.38, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.38

Correlation (3Y)
Calculated over the trailing 3-year period

0.40

Correlation (5Y)
Calculated over the trailing 5-year period

0.37

Correlation (All Time)
Calculated using the full available price history since Dec 19, 2019

0.36

Fundamentals

Market Cap

IMVT:

$7.76B

AXSM:

$12.69B

EPS

IMVT:

-$2.77

AXSM:

-$3.74

PB Ratio

IMVT:

9.10

AXSM:

232.46

Total Revenue (TTM)

IMVT:

$0.00

AXSM:

$708.24M

Gross Profit (TTM)

IMVT:

-$206.00K

AXSM:

$655.82M

EBITDA (TTM)

IMVT:

-$527.21M

AXSM:

-$172.72M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

IMVT vs. AXSM — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IMVT
IMVT Risk / Return Rank: 9292
Overall Rank
IMVT Sharpe Ratio Rank: 9191
Sharpe Ratio Rank
IMVT Sortino Ratio Rank: 9393
Sortino Ratio Rank
IMVT Omega Ratio Rank: 8888
Omega Ratio Rank
IMVT Calmar Ratio Rank: 9595
Calmar Ratio Rank
IMVT Martin Ratio Rank: 9494
Martin Ratio Rank

AXSM
AXSM Risk / Return Rank: 9797
Overall Rank
AXSM Sharpe Ratio Rank: 9797
Sharpe Ratio Rank
AXSM Sortino Ratio Rank: 9898
Sortino Ratio Rank
AXSM Omega Ratio Rank: 9696
Omega Ratio Rank
AXSM Calmar Ratio Rank: 9696
Calmar Ratio Rank
AXSM Martin Ratio Rank: 9797
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

IMVT vs. AXSM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Immunovant, Inc. (IMVT) and Axsome Therapeutics, Inc. (AXSM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


IMVTAXSMDifference
Sharpe ratioReturn per unit of total volatility

-1.27

Sortino ratioReturn per unit of downside risk

-1.37

Omega ratioGain probability vs. loss probability

1.39

1.59

-0.20

Calmar ratioReturn relative to maximum drawdown

6.77

7.95

-1.18

Martin ratioReturn relative to average drawdown

15.48

23.42

-7.93

IMVT vs. AXSM - Sharpe Ratio Comparison

The current IMVT Sharpe Ratio is 2.26, which is lower than the AXSM Sharpe Ratio of 3.53. The chart below compares the historical Sharpe Ratios of IMVT and AXSM, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

IMVT vs. AXSM - Drawdown Comparison

The maximum IMVT drawdown since its inception was -93.59%, which is greater than AXSM's maximum drawdown of -86.65%. Use the drawdown chart below to compare losses from any high point for IMVT and AXSM.


Loading charts...

Drawdown Indicators


IMVTAXSMDifference

Max Drawdown

Largest peak-to-trough decline

-93.59%

-86.65%

-6.94%

Max Drawdown (1Y)

Largest decline over 1 year

-20.98%

-18.50%

-2.48%

Max Drawdown (3Y)

Largest decline over 3 years

-69.88%

-34.83%

-35.05%

Max Drawdown (5Y)

Largest decline over 5 years

-70.38%

-72.91%

+2.53%

Max Drawdown (10Y)

Largest decline over 10 years

-81.26%

Current Drawdown

Current decline from peak

-27.72%

-2.87%

-24.85%

Average Drawdown

Average peak-to-trough decline

-53.85%

-39.40%

-14.45%

Ulcer Index

Depth and duration of drawdowns from previous peaks

9.15%

6.27%

+2.88%

Volatility

IMVT vs. AXSM - Volatility Comparison

Immunovant, Inc. (IMVT) has a higher volatility of 15.09% compared to Axsome Therapeutics, Inc. (AXSM) at 8.92%. This indicates that IMVT's price experiences larger fluctuations and is considered to be riskier than AXSM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


IMVTAXSMDifference

Volatility (1M)

Calculated over the trailing 1-month period

15.09%

8.92%

+6.17%

Volatility (6M)

Calculated over the trailing 6-month period

45.21%

33.16%

+12.05%

Volatility (1Y)

Calculated over the trailing 1-year period

62.87%

41.74%

+21.13%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

74.94%

70.26%

+4.68%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

78.27%

90.40%

-12.13%

Dividends

IMVT vs. AXSM - Dividend Comparison

Neither IMVT nor AXSM has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

IMVT vs. AXSM - Financials Comparison

This section allows you to compare key financial metrics between Immunovant, Inc. and Axsome Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M200.00M202220232024202520260
191.20M
(IMVT) Total Revenue
(AXSM) Total Revenue
Values in USD except per share items

Frequently Asked Questions


IMVT and AXSM have a correlation of 0.38, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

IMVT has higher volatility (15.09%) compared to AXSM (8.92%). In terms of maximum drawdown, IMVT dropped -93.59% vs AXSM's -86.65%.

AXSM currently has the higher Sharpe Ratio (3.53 vs 2.26), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for IMVT and AXSM

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer